References
- Kuppermann BD. Ocriplasmin for pharmacologic vitreolysis. Retina 2012;32:225–228
- Syed YY, Dhillon S. Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion. Drugs 2013;73:1617–1625
- Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012;367:606–615
- Haller JA, Stalmans P, Benz MS, et al. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology 2015;122:117–122
- Warrow DJ, Lai MM, Patel A, et al. Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin. Am J Ophthalmol 2015;159:20–30
- Lommatzsch AP, Gutfleisch M, Dietzel M, et al. Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin. Klin Monbl Augenheilkd 2014;231:909–914
- Kim BT, Schwartz SG, Smiddy WE, et al. Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 2013;44:334–343
- Singh RP, Li A, Bedi R, et al. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 2014;98:356–360
- Itoh Y, Kaiser PK, Singh RP, et al. Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography. Ophthalmology 2014;121:2506–2507
- Nagpal M, Mehta V, Nagpal K. Macular hole progression after intravitreal bevacizumab for hemicentral retinal vein occlusion. Case Rep Ophthalmol Med 2011;2011:679751
- Casswell E, Fernandez-Sanz G, Mitry D, et al. Macular hole progression following ocriplasmin intravitreal injection. Case Rep Ophthalmol Med 2014;2014:403461
- Chod RB, Goodrich C, Saxena S, Akduman L. Lamellar macular hole after intravitreal ocriplasmin injection. BMJ Case Rep 2015;2015. doi: 10.1136/bcr-2014-207810
- Freund KB, Shah SA, Shah VP. Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye 2013;27:773–774
- Hager A, Seibel I, Riechardt A, et al. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes? Br J Ophthalmol 2015;99:635–638.
- Fahim AT, Khan NW, Johnson MW. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol 2014;132:484–486
- Thanos A, Hernandez-Siman J, Marra KV, Arroyo JG. Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection. Retin Cases Brief Rep 2014;8:330–332
- Chen W, Mo W, Sun K, et al. Microplasmin degrades fibronectin and laminin at vitreoretinal interface and outer retina during enzymatic vitrectomy. Curr Eye Res 2009;34:1057–1064
- Byström B, Virtanen I, Rousselle P, et al. Distribution of laminins in the developing human eye. Invest Ophthalmol Vis Sci 2006;47:777–785
- de Smet MD, Jonckx B, Vanhove M, et al. Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 2012;53:8208–8213
- Stalmans P, Girach A. Vitreous levels of active ocriplasmin following intravitreal injection: results of an ascending exposure trial. Invest Ophthalmol Vis Sci 2013;54:6620–6627
- Theodossiadis GP, Grigoropoulos VG, Theodoropoulou S, et al. Spontaneous resolution of vitreomacular traction demonstrated by spectral-domain optical coherence tomography. Am J Ophthalmol 2014;157:842–851